The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorSeoul National University Bundang Hospital

About this trial

To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.

Eligibility criteria

Qualifiers

The patients who proved H. pylori infection following three methods

positive rapid urease test (CLOtest)

histologic evidence of H. pylori by modified Giemsa staining

positive Urea breath test

Disqualifiers

Patients who received eradication therapy for H. pylori infection, previously

H. pylori eradication failure because of poor compliance

the administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks

Advanced gastric cancer or other malignancy

Trial design

Treatments tested in this trial

  • 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)
  • 7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)
  • 7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]
  • 7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)

Treatment groups

600 Participants
are divided into 4 treatment groups